These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 24886908)

  • 1. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
    Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
    JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
    Insel PS; Hansson O; Mattsson-Carlgren N
    JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.
    Papp KV; Maruff P; Rentz DM; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):846-856. PubMed ID: 39044493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease.
    Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Porter T; Ames D; Fowler C; Rainey-Smith S; Snyder PJ; Martins RN; Salvado O; Bourgeat P; Rowe CC; Masters CL; Maruff P
    Neurology; 2016 Apr; 86(17):1635-42. PubMed ID: 27029632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
    Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
    Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.
    Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial.
    Papp KV; Rentz DM; Maruff P; Sun CK; Raman R; Donohue MC; Schembri A; Stark C; Yassa MA; Wessels AM; Yaari R; Holdridge KC; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2021; 8(1):59-67. PubMed ID: 33336226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease.
    Insel PS; Kumar A; Hansson O; Mattsson-Carlgren N;
    Neurology; 2023 Jul; 101(1):e20-e29. PubMed ID: 37085326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.
    Amariglio RE; Donohue MC; Marshall GA; Rentz DM; Salmon DP; Ferris SH; Karantzoulis S; Aisen PS; Sperling RA;
    JAMA Neurol; 2015 Apr; 72(4):446-54. PubMed ID: 25706191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.